Drug Profile
Teslexivir - Vaxart
Alternative Names: AP 611; AP611074; BTA-074; TeslexivirLatest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Anaconda Pharma
- Developer Anaconda Pharma; Vaxart
- Class Antivirals; Benzoic acids; Hydrazines; Piperidines; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Condylomata acuminata; Recurrent respiratory papillomatosis
Most Recent Events
- 03 Sep 2021 Discontinued - Clinical-Phase-Unknown for Recurrent respiratory papillomatosis in USA (Topical) (Vaxart pipeline, September 2021)
- 03 Sep 2021 Discontinued - Phase-II for Condylomata acuminata in Ecuador, Serbia, Chile, Argentina, France (Topical) (Vaxart pipeline, September 2021)
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Recurrent-respiratory-papillomatosis in USA (Topical, Gel)